Effects of Venlafaxine ER on Blood Pressure during the Acute Treatment of Major Depressive Patients.
- Author:
Ho Jun SEO
1
;
Jae Won SUH
;
Young Eun JUNG
;
Seok Beom KIM
;
Jeong Ho CHAE
;
Tae Youn JUN
;
Kwang Soo KIM
;
Won Myong BAHK
Author Information
1. Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Venlafaxine;
Elevation of blood pressure;
Major depressive disorder
- MeSH:
Antidepressive Agents, Tricyclic;
Blood Pressure;
Cyclohexanols;
Depressive Disorder, Major;
Humans;
Hypertension;
Incidence;
Norepinephrine;
Obesity;
Paroxetine;
Risk Factors;
Serotonin;
Venlafaxine Hydrochloride
- From:Korean Journal of Psychopharmacology
2008;19(1):46-52
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Venlafaxine is an antidepressant with a dual action of blocking reuptake of both serotonin and norepinephrine at therapeutic dose like some tricyclic antidepressants. However it may share the relative safety of SSRIs in overdosage and cardiotoxicity. One common concern for 1st line use of venlafaxine is the risk of hypertension. There have been some controversies about this adverse effect. In present study, we evaluate the effects of venlafaxine on blood pressure in therapeutic dose in acute treatment of major depressive patients. METHODS: The sample consisted of 65 major depressive patients who taken venlafaxine and 65 patients taken paroxetine, respectively. Blood pressure and other variables were evaluated in these subjects at baseline, 1 week, and 4 week of acute phase therapy, and mean blood pressure was compared each other by analysis of covariates. The incidence of sustained elevation of blood pressure during the study period was evaluated and stratified by age, sex, past history of hypertension, obesity, and dose of medication. These data were compared in two groups by chi square test and Fisher's Exact Test. RESULTS: At 1 week point, there were no significant differences between the two groups in mean blood pressure and other variables when controlling the baseline data. But at 4 week point, there was significant difference in mean diastolic pressure change between the two groups (venlafaxine group, -0.20+/- 6.98 mmHg;paroxetine group, 0.82+/-6.75 mmHg, p=0.020). When stratified by obesity (BMI>25), there was also significant difference in mean systolic and diastolic pressure change between the two groups at 4 week point (p=0.002;p=0.026). When comparing the incidence rate of sustained elevation of blood pressure during the study periods, only in venlafaxine group, three subjects developed elevation of blood pressure. When stratified the venlafaxine group with various factors, the incidence rate in the subjects who used high dose of venlafaxine (225 mg/day) was significantly different with those who used lower dose (below 225 mg/day). CONCLUSION: Our findings suggest that the use of venlafaxine can be associated with sustained elevation of blood pressure though used in therapeutic dose, but it can be detected with close monitoring and managed by reducing dose or hold the drug. In the future, to find out the risk factor of sustained elevation of blood pressure associated with venlafaxine use, large scaled and well controlled trials are needed.
